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Abstract 
Objectives: Patient Acceptable Symptom State (PASS) as an absolute state of well-being has 
shown promise as an outcome measure in many rheumatologic conditions. We assessed 
whether PASS may be effective in active diffuse cutaneous SSc. 
Methods: Data from the Phase 2 faSScinate trial were used, which compared tocilizumab vs. 
placebo over 48 weeks followed by an open-label tocilizumab period to 96 weeks. Three 
different types of PASS questions were evaluated at weeks 8, 24, 48 and 96, including would 
a current state be acceptable over time as yes vs. no response, and Likert scales about how 
acceptable a current state is if remaining over time. Additional outcomes assessed included 
mRSS, HAQ-DI, MD and Pt global VAS, CRP and ESR. 
Results: The placebo group consisted of 44 patients, and the tocilizumab group had 43 
patients. At baseline, 33% achieved PASS for all three PASS questions, with the proportion 
increasing to 69%, 71% and 78%, respectively at 96 weeks. Changes in PASS scores showed 
a moderately negative correlation with HAQ-DI, Pt and MD global VAS, which indicates 
expected improvements as PASS improved. PASS asking ‘Considering all of the ways your 
scleroderma has affected you how acceptable would you rate your level of symptoms?’ 
showed significant correlations with patient-reported outcomes and differentiating placebo 
vs. tocilizumab at 48 weeks (P=0.023). 
Conclusions: PASS may be used as patient-centered outcome in SSc especially as a 7-point 
Likert scale. Further validation is required to determine the utility as an outcome measure in 
trials and clinical practice. 
Trial registration number: ClinicalTrials.gov, number NCT01532869. 
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 Key Messages:PASS may be used as an effective patient-centered outcome in active 
diffuse cutaneous SSc. 
PASS is not the same as patient global assessment and may have added value in 
scleroderma. 
PASS is best assessed by level of symptom acceptability on a 7-point Likert scale. 
 
Introduction 
Systemic sclerosis (SSc) is a rare connective tissue disease that is characterized by 
fibrosis, inflammation and vascular damage. Clinical presentations are heterogeneous in 
nature, affecting the skin as well as pulmonary, cardiac, renal and gastrointestinal systems. 
Diffuse cutaneous SSc (dcSSc) has a high mortality (1). Clinical trials are ongoing to search 
for more effective treatment options, with the faSScinate trial assessing the effectiveness of 
tocilizumab, a novel IL-6 antibody in a randomized placebo controlled trial in dcSSc (2). 
Designing effective clinical trials in SSc has many challenges, which is in part due to 
the paucity of previous positive studies in SSc (2). The heterogeneity of the disease along 
with its varying clinical presentation makes it difficult to identify what outcome measures to 
assess. Often the modified Rodnan skin score (mRSS) is a primary endpoint (3). Patient 
reported outcomes have been used as a means of understanding what patients’ view as a 
satisfactory response to therapy. The concept of minimal clinically important difference 
(MCID) has been seen as a helpful way to provide complementary and more meaningful 
information to the endpoints of a trial (4, 5). However, Tubach et al. (6) have shown that 
patients care more about feeling good than they do about feeling better. For instance, if there 
is a large change in status but a patient is still in a moderate state of activity, this is not 
preferred, as the goal is likely to feel good, not to benchmark as feeling better than a previous 
state.  
Patient acceptable symptom state (PASS) is an outcome measure that allows for 
assessing either when patients feel good or when patients feel better. The OMERACT 
(Outcome Measures in Rheumatology) meeting in 2007 established the concept of PASS, 
however there has been no standardized question across diseases (5). Achieving a PASS is 
dependent on how this question is asked, but generally is used to describe the point beyond 
which patients consider themselves well (7). The aim of introducing PASS is to provide a 
means to translate a holistic look at patients’ symptoms into more clinically meaningful 
information.  
PASS has been demonstrated to be an effective assessment and robust marker in 
many rheumatologic diseases (8-11), although it is yet to be evaluated in SSc. Our aim was to 
assess the effectiveness of PASS as an outcome marker for SSc using patients from the 
faSScinate trial including relationships to other outcomes and if and when it could 




 This study uses data collected from patients enrolled in the faSScinate trial, which is 
outlined in detail by Khanna et al. (2). To summarize, this was a 48 week randomized control 
trial with another 48 weeks of open label extension, that enrolled 87 patients who had a 
diagnosis of SSc according to the 1980 American College of Rheumatology Criteria and 
demonstrated signs of active disease (12) and active dcSSc subset. Patients were randomized 
to tocilizumab (TCZ) 162 mg sc weekly or placebo (PBO) and were assessed at regular 
intervals. The primary outcome was modified Rodnan Skin Score (mRSS) assessed at 24 
weeks. At 24 weeks, the treating physician could place patients on rescue medication as 
deemed necessary, while all patients could be transitioned to TCZ at 48 weeks. While the 
results for the primary outcome resulted in a negative study, there was a clinically meaningful 
decline in mRSS over 48 weeks in the tocilizumab group compared with the placebo group as 
determined by MCID. 
 
Patient Acceptable Symptom State 
There has been no standardized question as to the best way to ask a patient whether 
they are in an acceptable symptom state (13). Previous studies have evaluated dichotomous 
and scaled patient reported outcomes as well as statistical approaches to define PASS (5, 8-
10). We evaluated three questions that considered dichotomous vs. scaled outcomes as well 
as the acceptability of symptoms vs. changes to baseline. 
PASS #1 was aimed at assessing level of acceptability of symptoms based on a scale. 
“Considering all of the ways your scleroderma has affected you over the last week, how 
acceptable would you rate your level of symptoms?” Responses were reported on a 7-point 
Likert scale with choices ranging from -3 (highly unacceptable) to 3 (highly acceptable). 
PASS #2 used the level of acceptability as a dichotomous outcome. “Think about all 
the ways that your scleroderma has affected you during the last week. If you were to remain 
for the next few months as you were in the last week, would this be acceptable to you?” 
Responses were reported as either Yes or No. 
PASS #3 asked for a change of symptoms “Has there been a change in how you 
would describe your level of functional impairment since you started the study?” Responses 
were reported on a 5-pont Likert scale with choices ranging from -2 (much worse) to 0 (no 
change) to 2 (much better). 
 
Outcomes assessed 
 Khanna et al. (14) recently provided suggestions as to the most relevant disease 
outcome markers to consider in trials on SSc. These included mRSS, percent predicted of 
forced vital capacity (%pFVC), physician global assessment (MD global VAS), patient 
global assessment (Pt global VAS), and health assessment questionnaire-disability index 
(HAQ-DI). We considered all of these outcomes with the exception of %pFVC, as successful 
treatment is expected to slow progression of lung disease rather than lead to improvement in 
symptoms. Additionally, we included C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) to assess systemic inflammation. Patients were evaluated at weeks 
8, 24, 48 and 96.  
 
Statistical Analysis 
Normality for each of the outcome markers was assessed using the Shapiro–Wilk test. 
Patient characteristics were analyzed using independent samples t-tests with two-tailed P 
values. The proportion of patients achieving PASS #1 and #3 was considered as a 1-point 
increase from their baseline visit score, whereas PASS #2 was having a response of “Yes.” 
Correlations were assessed using Goodman and Kruskal's gamma value due to the many tied 
ranks with respect to the PASS questions and other outcomes at weeks 8, 24, 48 and 96. 
Determining significance of PASS in differentiating patients on tocilizumab vs. placebo was 
done using Pearson Chi-square value. P-values < 0.05 were considered significant. All 
analysis was carried out using SPSS version 24. 
 
Results 
Patient characteristics comparing placebo vs. tocilizumab are presented in Table 1. 
There were 44 patients at baseline in the placebo group and 43 patients in the tocilizumab 
group. At baseline, PASS #1 had 32 (73%) and 35 (81%) patients scoring a 0 or less, 
respectively for placebo and tocilizumab. PASS #2 had 28 (63.6%) and 29 (69%) responding 
with a “No,” respectively. PASS #3 was designed to have a baseline of 0 suggesting no 
change, however only 36 (82%) and 32 (74%) responded with a baseline score of 0, 
respectively. There were no reports of patients refusing to answer PASS. 
All outcomes were non-normally distributed with the exception of age and mRSS. A 
greater number of patients were discontinued from the trial in the placebo group (n = 20) vs. 
the tocilizumab group (n = 16), but with no statistical significance identified. Similarly, 9 
(28%) patients required rescue meds in the placebo group compared to 3 (10%) in the 
tocilizumab group between 24 to 48 weeks, but without statistical significance. Baseline 
characteristics were similar between active and placebo (refer also to Table 1 and Figure 1 of 
the faSScinate paper) (2). 
 The three PASS questions are evaluated and compared in Table 2. The proportion of 
patients achieving PASS increased for all three questions as the trial progressed, with the 
proportions being similar across all three questionnaires at each visit. The majority of patients 
had achieved PASS by the end of the trial (69%, 71% and 78% for PASS #1, #2 and #3, 
respectively). 
PASS #1 at 48 weeks showed statistical significance in being able to differentiate 
those patients on placebo vs. tocilizumab (P value = 0.023) where a greater than or equal to 
one-point change on the Likert scale could differentiate tocilizumab from placebo. Pt global 
VAS and HAQ-DI score showed a moderately negative correlation across all three PASS 
questions. MD Global VAS also showed a moderately negative correlation that was 
statistically significant for PASS #2 and #3. Total mRSS, CRP and ESR did not show a 
correlation with any of the PASS questions. 
 
Discussion 
 This paper is the first to assess the usefulness of PASS in a RCT in SSc. We found 
that the majority of patients in the faSScinate study had achieved PASS by the end of the 
trial. Given the clinically meaningful changes identified with tocilizumab (2), PASS was able 
to differentiate between placebo and tocilizumab. 
Evaluating PASS in trials involving SSc appears to be a reliable means of 
complementing primary endpoints of studies by weighing up the benefits or harms that 
patients may experience from therapy. As a result, PASS has the benefit of being able to 
translate results from large trials to an individual level, thus providing further guidance for 
patient decisions (7). No patients refused to answer PASS, which along with previous studies 
suggests its acceptability (8).  
The PASS questions were moderately correlated with HAQ-DI score, Pt global VAS 
and MD global VAS. This means that as these disease outcomes improve, patients are more 
likely to enter into an acceptable symptom state. When assessing active dcSSc and drugs to 
improve skin and overall disease, it is not likely that most treatments will improve the GI 
involvement, Raynaud’s and other symptoms when softening skin and/or targeting lung 
function. Asking a PASS question is a holistic way to determine if the treatment is improving 
their quality of life overall. Patients likely consider the benefit of treatment, the side effects 
and their SSc symptoms altogether. The moderate correlation identifies that PASS is 
sufficiently different from these outcomes, suggesting that it may consider additional aspects 
of a patient’s disease state that our current outcome markers do not evaluate. Despite mRSS 
being the primary endpoint in many SSc trials (3), including the faSScinate trial (2), there 
was no correlation seen with PASS. This suggests that mRSS complements patient-reported 
outcome measures and may actually play a smaller role in affecting the patient’s symptom 
state than previously expected, at least for the degree of skin improvement that occurs during 
a RCT where the change is modest. An example of this is that hand function is often still 
quite impaired, as skin tends to soften more in proximal areas first. 
 Our findings support the use of PASS #1 in future clinical trials. Although an 
improvement of 1-point does not indicate whether patients have reached an absolute 
acceptable symptom state, it does serve to distinguish tocilizumab vs. placebo, which can be 
used as an endpoint in future clinical trials. Whereas PASS #2 only showed a trend towards 
statistical significance, it could serve as a reasonable alternative given its validation in 
previous trials (8, 16). The simple dichotomous outcome does indicate whether patients have 
reached an absolute acceptable symptom state, but concerns arise due to loss of statistical 
power in what is already a rare disease (5). We would advise against using PASS #3 given 
lack of statistical significance and patients misinterpreting the question. 
Although achieving PASS suggests a state of wellbeing, it is not synonymous with 
achieving perfect health (15). PASS #1 helps to instruct clinicians as to when their patients 
feel better from treatment. Conversely, PASS #2 gives clinicians a sense of when patients feel 
good and reach a level of contentment with their current symptoms. PASS #1 and #2 ask the 
current state acceptability whereas #3 is a change in state. The first two are an absolute state. 
It is difficult to interpret what it means to “achieve a PASS” to a patient with SSc and to 
their treating physician.  
There are inherent limitations in an exploratory analysis. When evaluating patients at 
48 weeks, a disproportionate number of patients between the placebo and tocilizumab groups 
received rescue medication, possibly limiting the ability of PASS to differentiate placebo vs. 
tocilizumab. For the patients remaining in the study up to 96 weeks (in the open label 
extension between 48 and 96 weeks), more patients entered into an acceptable symptom state, 
so a longer duration of placebo vs. tocilizumab could have provided more power to 
differentiate the two groups. Raynaud’s and gastrointestinal symptoms are examples of 
symptoms that may be strongly correlated with patients achieving PASS or not, which this 
study did not evaluate. 
 
Conclusion 
 In summary, PASS may be used as an effective outcome marker in SSc. PASS is 
likely to be most effective when evaluating the acceptability of symptoms based on a 7-point 
Likert scale. Further validation of PASS in clinical trials and practice in SSc are required to 
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Table 1 – Patient characteristics of placebo vs. tocilizumab 
 
BaselinePlacebo 
(n = 44)Tocilizumab 
(n = 43)PASS #1, # selecting “Score of -3 to 0” (%)a32 (73)35 (81)PASS #2, # selecting 
“No” (%)a28 (64)29 (69)PASS #3, # selecting “Score of 0” (%)a36 (82)32 (74)Age48 
(12.9)51 (11.7)Female, # (%)35 (80)32 (74)White, # (%)40 (91)38 (88)Duration of SSc, 
days595 (517)537 (418)Total mRSSb25.6 (5.9)26.5 (7.2)HAQ-DI scoreb1.36 (0.74)1.31 
(0.61)MD Global VAS, mmb60.1 (15.2)64.1 (15.1)Pt Global VAS, mmb61.9 (21.0)60.0 
(18.3)CRP, mg/Lb10.5 (13.6)10.5 (13.7)ESR, mm/hb26.2 (21.2)31.0 (18.8)Follow up during 
the trialDiscontinued from trial, # (%)20 (45)16 (37)Rescue Medication    By Week 48, #yes 
(% of n) 
By Week 96, #yes (% of n)9 (28) 
9 (38)3 (10) 
6 (22) 
All values are mean (SD) unless stated otherwise.  
aPossible scores are: PASS #1, -3 (highly unacceptable) to 3 (highly acceptable); PASS #2, 
yes/no; PASS #3, -2 (much worse) to 0 (no change) to 2 (much better). 
bPossible scores are: mRSS, 0-51; HAQ-DI, 0-3; Global VAS, 0-100; upper limit of normal 
for CRP is 3 mg/L; ESR is dependent on age and gender. 
PASS – Patient Acceptable Symptom State; mRSS – modified Rodnan Skin Score; HAQ-DI 
– Health Assessment Score-Disability Index; MD – physician; Pt – patient; VAS – Visual 
Analog Scale; CRP – C-Reactive Protein; ESR – Erythrocyte Sedimentation Rate. 
 
 
Table 2 – Evaluation of PASS Questions 
 
PASS #1PASS #2PASS #3Proportion achieving PASS a 
Week 8, # (%) 
Week 24, # (%) 
Week 48, # (%) 
























0.611Correlations with outcome markers at Week 96 (Gamma value)c 
MD Global VAS 
Pt Global VAS 
 HAQ-DI score 























For Proportion achieving PASS and Tocilizumab vs. Placebo sections, PASS #1 and #3 
considered those patients with a 1-point increase from baseline. PASS #2 considered patients 
with a response of “Yes.” 
aPercentages were calculated based on available data for each time period. 
bp-values were calculated using Chi-square analysis.  
cValues were calculated using Goodman and Kruskal's gamma. Negative value indicates a 
negative correlation, in which a decrease in relative relates with improvement in PASS score. 
* indicates P value <0.05, ** indicates P value <0.01 
 
ion to the 2 tables in Results. 
In order to fit the requirements of a concise report, only 2 tables are permitted. The last 
two rows of this table do provide some valuable information to what is referenced in 
the Results section. They were simplified in this table in hopes of making it easier for 
the reader to understand and digest. 
 
 
 
